First AD

Second AD

Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer

Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.

Approved Treatment Options for Patients with mCRPC

The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Patient Profile: A 78-Year-Old Man with mCRPC

Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

Closing Thoughts on the Future of mCRPC Treatment